137 related articles for article (PubMed ID: 38557163)
1. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
[TBL] [Abstract][Full Text] [Related]
2. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
[TBL] [Abstract][Full Text] [Related]
3. Optimal composition and position of histidine-containing tags improves biodistribution of
Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
[TBL] [Abstract][Full Text] [Related]
4. Sortase-Mediated Site-Specific Conjugation and
Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of
Bragina O; Chernov V; Schulga A; Konovalova E; Garbukov E; Vorobyeva A; Orlova A; Tashireva L; Sörensen J; Zelchan R; Medvedeva A; Deyev S; Tolmachev V
J Nucl Med; 2022 Apr; 63(4):528-535. PubMed ID: 34385343
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
8. Direct In Vivo Comparison of
Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
[TBL] [Abstract][Full Text] [Related]
9. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
[TBL] [Abstract][Full Text] [Related]
10. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
Mol Pharm; 2019 Mar; 16(3):995-1008. PubMed ID: 30608701
[TBL] [Abstract][Full Text] [Related]
11. An improved
Khodadust F; Ahmadpour S; Aligholikhamseh N; Abedi SM; Hosseinimehr SJ
Eur J Med Chem; 2018 Jan; 144():767-773. PubMed ID: 29291444
[TBL] [Abstract][Full Text] [Related]
12. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
[TBL] [Abstract][Full Text] [Related]
13. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
[TBL] [Abstract][Full Text] [Related]
14. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
15. A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors.
Varmira K; Hosseinimehr SJ; Noaparast Z; Abedi SM
Nucl Med Biol; 2013 Nov; 40(8):980-6. PubMed ID: 23953624
[TBL] [Abstract][Full Text] [Related]
16. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
17. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
18.
Molavipordanjani S; Khodashenas S; Abedi SM; Moghadam MF; Mardanshahi A; Hosseinimehr SJ
Eur J Pharm Sci; 2020 May; 148():105312. PubMed ID: 32198014
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
